Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christiane Baldes is active.

Publication


Featured researches published by Christiane Baldes.


Molecular Pharmaceutics | 2010

Vitamin E TPGS P-Glycoprotein Inhibition Mechanism: Influence on Conformational Flexibility, Intracellular ATP Levels, and Role of Time and Site of Access

Eva-Maria Collnot; Christiane Baldes; Ulrich F. Schaefer; Kevin J. Edgar; Michael F. Wempe; Claus-Michael Lehr

Previous work conducted in our laboratories established the notion that TPGS 1000 (d-alpha-tocopheryl polyethylene glycol 1000 succinate), a nonionic surfactant, modulates P-glycoprotein (P-gp) efflux transport via P-gp ATPase inhibition. The current in vitro research using Caco-2 cells was conducted to further explore the P-gp ATPase inhibition mechanism. Using a monoclonal CD243 P-gp antibody shift assay (UIC2), we probed P-gp conformational changes induced via TPGS 1000. In the presence of TPGS 1000, UIC2 binding was slightly decreased. TPGS 1000 does not appear to be a P-gp substrate, nor does it function as a competitive inhibitor in P-gp substrate efflux transport. The reduction in UIC2 binding with TPGS 1000 was markedly weaker than with orthovanadate, data ruling out trapping P-gp in a transition state by direct interaction with one or both of the P-gp ATP nucleotide binding domains. An intracellular ATP depletion mechanism could be ruled out in the UIC2 assay, and by monitoring intracellular ATP levels in the presence of TPGS 1000. Indicating slow distribution of TPGS 1000 into the membrane, and in agreement with an intramembranal or intracellular side of action, Caco-2 cell monolayer experiments preincubated with TPGS 1000 produce stronger substrate inhibitory activity than those conducted by direct substrate and surfactant coapplication.


Cell and Tissue Research | 2006

Towards an in vitro model of cystic fibrosis small airway epithelium : characterisation of the human bronchial epithelial cell line CFBE41o-

Carsten Ehrhardt; Eva-Maria Collnot; Christiane Baldes; Ulrich Becker; Michael Laue; Kwang-Jin Kim; Claus-Michael Lehr

The CFBE41o- cell line was generated by transformation of cystic fibrosis (CF) tracheo-bronchial cells with SV40 and has been reported to be homozygous for the ΔF508 mutation. A systematic characterisation of these cells, which however, is a pre-requisite for their use as an in vitro model, has not been undertaken so far. Here, we report an assessment of optimal culture conditions, the expression pattern of drug-transport-related proteins and the stability/presence of the CF transmembrane conductance regulator (CFTR) mutation in the gene and gene product over multiple passages. The CFBE41o- cell line was also compared with a wild-type airway epithelial cell line, 16HBE14o-, which served as model for bronchial epithelial cells in situ. The CFBE41o- cell line retains at least some aspects of human CF bronchial epithelial cells, such as the ability to form electrically tight cell layers with functional cell-cell contacts, when grown under immersed (but not air-interfaced) culture conditions. The cell line is homozygous for ΔF508-CFTR over multiple passages in culture and expresses a number of proteins relevant for pulmonary drug absorption (e.g. P-gp, LRP and caveolin-1). Hence, the CFBE41o- cell line should be useful for studies of CF gene transfer or alternative treatment with small drug molecules and for the gathering of further information about the disease at the cellular level, without the need for primary culture.


FEBS Journal | 2007

The heat shock protein 70 molecular chaperone network in the pancreatic endoplasmic reticulum − a quantitative approach

Andreas Weitzmann; Christiane Baldes; Johanna Dudek; Richard Zimmermann

Traditionally, the canine pancreatic endoplasmic reticulum (ER) has been the workhorse for cell‐free studies on protein transport into the mammalian ER. These studies have revealed multiple roles for the major ER‐luminal heat shock protein (Hsp) 70, IgG heavy chain‐binding protein (BiP), at least one of which also involves the second ER‐luminal Hsp70, glucose‐regulated protein (Grp) 170. In addition, at least one of these BiP activities depends on Hsp40. Up to now, five Hsp40s and two nucleotide exchange factors, Sil1 and Grp170, have been identified in the ER of different mammalian cell types. Here we quantified the various proteins of this chaperone network in canine pancreatic rough microsomes. We also characterized the various purified proteins with respect to their affinities for BiP and their effect on the ATPase activity of BiP. The results identify Grp170 as the major nucleotide exchange factor for BiP, and the resident ER‐membrane proteins ER‐resident J‐domain protein 1 plus ER‐resident J‐domain protein 2/Sec63 as prime candidates for cochaperones of BiP in protein transport in the pancreatic ER. Thus, these data represent a comprehensive analysis of the BiP chaperone network that was recently linked to two human inherited diseases, polycystic liver disease and Marinesco–Sjögren syndrome.


Laboratory Investigation | 2005

Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors

Kamilla Piotrowska; Elke Kleideiter; Thomas E. Mürdter; Sebastian Taetz; Christiane Baldes; Ulrich F. Schaefer; Claus-Michael Lehr; Ulrich Klotz

Telomerase inhibition represents a promising approach to anticancer treatment. In order to clarify the therapeutic potential of telomerase inhibitors we examined different substances (small molecule compounds BIBR1532 and BRACO19, as well as hTR antisense oligonucleotides 2′-O-methyl RNA and PNA) in A-549, MCF-7, and Calu-3 cell lines in a cell-free TRAP assay. We demonstrated that each of the tested agents inhibited telomerase in all used cell lines and that the antisense oligonucleotides represent the most potent inhibitors. Interestingly, upon evaluating the specificity of telomerase inhibitors we found out that not all agents acted specifically against telomerase. We observed that BRACO19 and PNA had an inhibitory effect also on PCR amplification of the TSR8 oligonucleotide which is provided in the TRAPEZE® kit as a PCR control. By modifying the experimental protocol and using a different reverse primer we were able to enhance PNA selectivity, although the PCR inhibition of the TSR8 control template by BRACO19 could not be prevented. We propose an explanation for the lack of target specificity and suggest caution when testing putative telomerase inhibitors, as it appears that some of those substances may not affect specifically telomerase or telomeric G-rich sequences and thus can lead to the misinterpretation of experimental results.


International Journal of Pharmaceutics | 2008

Decomposition of the Telomere-Targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential

Sebastian Taetz; Thomas E. Mürdter; J. Zapp; S. Boettcher; Christiane Baldes; Elke Kleideiter; Kamilla Piotrowska; Ulrich F. Schaefer; Ulrich Klotz; Claus-Michael Lehr

The stability of the acridine-based telomere-targeting agent BRACO19, a G-quadruplex stabilizing substance, was tested at different pH, temperature and in different dissolution media. Analysis was performed by HPLC. Decomposition products were examined by LC/MS and NMR. The TRAP assay was used to determine the inhibitory potential of the decomposition products on telomerase activity. The results show that the stability of BRACO19 strongly depends on pH and temperature. Decomposition was fastest at physiological pH and temperature while the type of dissolution medium had no major influence on stability. The most probable mechanism for this decomposition seems to be a hydrolysis of the amide bonds in position 3 and 6 of the acridine ring and/or a deamination of the phenyl ring. The decomposition products showed a reduced inhibitory potential compared to the parent compound BRACO19. The results demonstrate that the preparation of dosage forms and their storage conditions will have an important influence on the stability--and hence biological efficacy--of BRACO19 and related substances.


Molecular Pharmaceutics | 2007

Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity.

Eva-Maria Collnot; Christiane Baldes; Michael F. Wempe; Reinhard Kappl; Jürgen Hüttermann; John A. Hyatt; Kevin J. Edgar; Ulrich F. Schaefer; Claus-Michael Lehr


Journal of Controlled Release | 2006

Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers

Eva-Maria Collnot; Christiane Baldes; Michael F. Wempe; John A. Hyatt; Lisa Navarro; Kevin Joseph Edgar; Ulrich F. Schaefer; Claus-Michael Lehr


European Journal of Pharmaceutics and Biopharmaceutics | 2009

The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells.

Sebastian Taetz; Noha Nafee; Julia Beisner; Kamilla Piotrowska; Christiane Baldes; Thomas E. Mürdter; Hanno Huwer; Marc Schneider; Ulrich F. Schaefer; Ulrich Klotz; Claus-Michael Lehr


Journal of Ocular Pharmacology and Therapeutics | 2007

Expression of ABC-Transporters in Human Corneal Tissue and the Transformed Cell Line, HCE-T

Ulrich Becker; Carsten Ehrhardt; Nicole Daum; Christiane Baldes; Ulrich F. Schaefer; Klaus W. Ruprecht; Kwang-Jin Kim; Claus-Michael Lehr


European Journal of Pharmaceutics and Biopharmaceutics | 2006

Development of a fluorescence-based assay for screening of modulators of human Organic Anion Transporter 1B3 (OATP1B3)

Christiane Baldes; P. Koenig; Dirk Neumann; Hans-Peter Lenhof; Oliver Kohlbacher; Claus-Michael Lehr

Collaboration


Dive into the Christiane Baldes's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge